---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-301185"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2023-12-21T23:59:59+00:00"
generated_at: "2026-06-07T08:53:50.073469+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AbbVie extends option for Aldeyra's reproxalap with $5M fee

## Summary
- AbbVie paid $5M non-refundable fee to extend option period for reproxalap co-development license.
- Exercise period now until 10 business days after FDA approval or 18 months from Oct 31, 2023.
- Option fee will be credited against upfront cash if License Agreement is signed.
- Reproxalap is Aldeyra's NDA-stage treatment for dry eye disease.

## SEC filing metadata
- accession: 0001193125-23-301185
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2023-12-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000119312523301185/0001193125-23-301185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000119312523301185/d603612d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-301185
- JSON: https://secwatch.observer/filing/0001193125-23-301185.json
- Plain text: https://secwatch.observer/filing/0001193125-23-301185.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.